531739 Stock Overview
Gennex Laboratories Limited engages in manufacturing, marketing, and selling of bulk drugs, intermediates, and biotech products.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Gennex Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹16.27 |
| 52 Week High | ₹21.89 |
| 52 Week Low | ₹5.75 |
| Beta | 0.58 |
| 1 Month Change | 0.68% |
| 3 Month Change | -12.01% |
| 1 Year Change | 172.53% |
| 3 Year Change | 146.89% |
| 5 Year Change | 410.03% |
| Change since IPO | 1,255.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| 531739 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -1.6% | 1.4% | 2.8% |
| 1Y | 172.5% | 57.2% | 46.6% |
Return vs Industry: 531739 exceeded the Indian Pharmaceuticals industry which returned 55.9% over the past year.
Return vs Market: 531739 exceeded the Indian Market which returned 46.4% over the past year.
Price Volatility
| 531739 volatility | |
|---|---|
| 531739 Average Weekly Movement | 9.5% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: 531739's share price has been volatile over the past 3 months.
Volatility Over Time: 531739's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 118 | Arihant Baid | www.gennexlab.com |
Gennex Laboratories Limited engages in manufacturing, marketing, and selling of bulk drugs, intermediates, and biotech products. The company offers active pharmaceutical ingredients, including Guaifenesin, Methocarbamol, Fluconazole, Mephenesin, Phenazopyridine Hcl, Melitracen Hcl, Allopurinol, Ketoconazole, Domperidone, Flupentixol Di-Hydrochloride, Chlorphenesin, Allopurinol, Ketoconazole, and Others. It operates in India, Bangladesh, Belgium, Canada, Colombia, Cuba, Egypt, El Salvador, Germany, Guatemala, Iran, Kenya, Mexico, the Netherlands, Peru, Russia, Saudi Arabia, Singapore, Spain, Switzerland, Turkey, Uruguay, and Vietnam.
Gennex Laboratories Limited Fundamentals Summary
| 531739 fundamental statistics | |
|---|---|
| Market cap | ₹3.70b |
| Earnings (TTM) | ₹107.16m |
| Revenue (TTM) | ₹718.68m |
34.5x
P/E Ratio5.1x
P/S RatioIs 531739 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 531739 income statement (TTM) | |
|---|---|
| Revenue | ₹718.68m |
| Cost of Revenue | ₹355.88m |
| Gross Profit | ₹362.81m |
| Other Expenses | ₹255.64m |
| Earnings | ₹107.16m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.47 |
| Gross Margin | 50.48% |
| Net Profit Margin | 14.91% |
| Debt/Equity Ratio | 23.6% |
How did 531739 perform over the long term?
See historical performance and comparison